The review’s central thesis is that atopic dermatitis itch emerges from a dynamic, bidirectional conversation between keratinocytes, the dominant cells of the epidermis, and the sensory neurons that innervate the skin. When the epithelial barrier breaks down, whether through genetic vulnerability, environmental insult, or the mechanical trauma of scratching, stressed keratinocytes release a cocktail of damage-induced mediators known as alarmins. Chief among these are thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25). These signals do not merely recruit immune cells; they act directly on cutaneous nerve fibers, activating or sensitizing them and thereby amplifying itch transmission. The result is a self-reinforcing itch-scratch-injury cycle in which each bout of scratching further damages the barrier, releases more pruritogens, and entrenches neural hypersensitivity.

TSLP has emerged as perhaps the clearest example of epithelial-to-neural signaling. This keratinocyte-derived cytokine signals through a receptor complex comprising the TSLP receptor and the IL-7 receptor alpha subunit, potently activating dendritic cells and skewing immunity toward a type 2 profile dominated by Th2 cells, mast cells, and natural killer T cells. Serum TSLP is significantly elevated in patients with atopic dermatitis and correlates with disease severity. Crucially, work by Wilson and colleagues showed that calcium-dependent ORAI1/NFAT signaling in keratinocytes regulates TSLP release, and that TSLP in turn directly activates TRPA1-positive sensory neurons to induce itch. The same epithelial-neuronal crosstalk operates in airway epithelial cells, suggesting a mechanistic bridge that may help explain the atopic march, the progression from eczema to asthma and allergic rhinitis.

IL-33 presents a more complicated picture. It induces type 2 cytokines including IL-4, IL-5, and IL-13, synergizes with IL-4 to drive production of IL-31, a key pruritogen, and enhances histamine-induced itch through mast cell activation and IL-13 release. Its receptor, ST2, is expressed on dorsal root ganglion neurons in both humans and mice, and IL-33 can sensitize these neurons to IL-4- and IL-13-mediated signaling. In the spinal cord, IL-33/ST2 signaling activates an astrocytic JAK2-STAT3 pathway that engages the gastrin-releasing peptide (GRP) axis, a canonical spinal itch circuit whose serum levels correlate with disease severity and itch intensity in patients. Yet the review is candid about the limits of the evidence: some studies found no correlation between circulating IL-33 and pruritus severity, and neuronal-restricted IL-33 receptor signaling proved dispensable for itch in an AD-like mouse model. Genetic variants in the IL33 gene have been linked to itch severity, hinting that predisposition modulates the pathway, but a direct causal role in human AD itch remains unproven.

The strongest clinical case belongs to the type 2 cytokines IL-4 and IL-13. Both can directly activate mouse and human sensory neurons, and IL-4 additionally sensitizes neurons to a broad range of pruritogens. Mechanistically, chronic itch requires neuronal IL-4Ralpha-JAK1 signaling: deleting IL-4Ralpha or JAK1 specifically in sensory neurons markedly reduces scratching in mice, and JAK inhibition relieves recalcitrant chronic itch in patients unresponsive to conventional immunosuppressants. Recent work with human dorsal root ganglion neurons showed that IL-4, IL-13, and IL-33 sensitize neurons to both histaminergic and non-histaminergic pruritogens within just two hours of exposure, with IL-4 and IL-13 inducing a shared, cytokine-specific transcriptional program distinct from that triggered by other inflammatory stimuli. Type 2 immunity, in other words, has been co-opted by the nervous system itself.

Interleukin-31 stands out as the most thoroughly validated cytokine linking immune activation to neuronal itch signaling. Produced mainly by Th2 cells but also by basophils, macrophages, and, as recent evidence shows, M2-polarized macrophages in lesional skin, IL-31 signals through a receptor complex of IL-31 receptor A and the oncostatin M receptor. In a restricted population of IL-31RA-positive, TRPV1-positive, TRPA1-positive sensory neurons, IL-31 triggers intracellular calcium release and ERK activation. It also induces rapid STAT3 activation in these neurons, and STAT3 transcriptionally upregulates the IL-31 receptor itself, creating a feed-forward loop that amplifies sensitivity. Beyond the periphery, IL-31 induces expression of B-type natriuretic peptide (BNP), encoded by the NPPB gene, which transmits itch signals through natriuretic peptide receptor A in the spinal cord, and promotes axonal elongation and branching in small-diameter sensory neurons, providing a mechanistic explanation for the increased cutaneous nerve fiber density seen in chronic disease. The clinically approved antibody nemolizumab targets this axis.

The review also highlights periostin, a matrix protein secreted by dermal fibroblasts downstream of type 2 inflammation, as a conserved pruritogen that induces itch across mice, dogs, and non-human primates. Periostin binds integrin alphavbeta3 on sensory neurons, triggering extracellular calcium influx and spontaneous firing in an itch-related, TRPV1- and TRPA1-dependent manner, with BNP as a key neuropeptide effector. Remarkably, periostin also reciprocally induces keratinocyte-derived TSLP through the JAK2-STAT3 pathway, closing a feed-forward epithelial-neuronal loop. Serum periostin levels are elevated in patients and correlate with disease severity, positioning it as an emerging therapeutic target.

Neurotrophic factors and neuropeptides add a structural dimension to the story. Nerve growth factor (NGF) is markedly elevated in the stratum corneum of lesional skin, correlating with itch severity, erythema, xerosis, eosinophil counts, and serum lactate dehydrogenase, and blocking NGF signaling ameliorates dermatitis and scratching in the NC/Nga mouse model. Substance P, classically acting through the neurokinin-1 receptor, drives neurogenic inflammation and correlates with itch intensity and even depression scores, but recent work shows it can also evoke non-histaminergic itch by activating MRGPRX2 on mast cells and MRGPRA1 on sensory neurons, and it has displayed paradoxically protective, barrier-restoring effects in some experimental settings. Calcitonin gene-related peptide (CGRP) promotes keratinocyte proliferation and epidermal thickening, with atopic keratinocytes showing heightened CGRP responsiveness and exaggerated hyperplasia. Artemin, a glial cell line-derived neurotrophic factor, is upregulated in lesional skin downstream of both the aryl hydrocarbon receptor, activated by organic components of air pollution, and toll-like receptor signaling triggered by house dust mite, linking environmental exposures directly to sensory nerve sprouting and warmth-provoked itch.

Woven through all of these pathways is the JAK-STAT signaling cascade, which the authors identify as the most clinically validated convergence point between immune cytokines and pruritus. Lesional skin from patients shows broad activation of phosphorylated JAK1-3 and STAT2/3 across epidermal and dermal compartments, and a spontaneous mouse model with an epidermal JAK1 gain-of-function mutation demonstrated that keratinocyte-intrinsic JAK1 hyperactivation alone is sufficient to drive barrier dysfunction, chronic inflammation, and pruritus. JAK1 is also enriched in pruriceptive neurons, where it mediates IL-4, IL-13, and IL-31 signaling, and electrophysiological studies suggest that JAK1-selective inhibitors such as upadacitinib can directly modulate cortical neuronal activity, hinting at central neuromodulatory effects beyond immune suppression.

The conceptual payoff of the review is a continuum model of chronic itch. It begins as peripherally driven, epithelial-mediated signaling, but repeated stimulation progressively sensitizes sensory neurons and broadens their responsiveness until itch becomes partially decoupled from peripheral cues and increasingly reflects structural and functional remodeling within itch-processing circuits. The finding that even non-lesional skin of patients exhibits heightened cowhage-induced itch underscores that altered sensory responsiveness is an intrinsic feature of the disease, not merely a byproduct of visible inflammation. The authors argue that early intervention to interrupt repetitive itch-scratch cycles, before central sensitization and neuronal remodeling become entrenched, may be essential to prevent long-term chronicity, treatment resistance, and the psychological comorbidities that so often shadow this disease.

Subject of Research: Neuroimmune mechanisms of chronic itch in atopic dermatitis

Article Title: Pruritogenic mediators in atopic dermatitis: mechanisms of neurogenic crosstalk

Article References: Wong, L.-S., Yang, J.-H., Yen, Y.-T., & Yang, J.-L. (2026). Pruritogenic mediators in atopic dermatitis: mechanisms of neurogenic crosstalk. Journal of Cutaneous Immunology and Allergy, 9, Article 16460. https://doi.org/10.3389/jcia.2026.16460

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.16460

Keywords: atopic dermatitis, chronic itch, pruritus, keratinocytes, sensory neurons, TSLP, IL-31, IL-4, IL-13, JAK-STAT signaling, neuropeptides, neuroimmune crosstalk

The authors trace a decisive shift in how the field understands the disorder. Early research attributed dry eye primarily to insufficient tear secretion or excessive tear evaporation, treating the tear film as the sole culprit. Advances in mechanistic research have moved the academic consensus away from that tear film-centric perspective toward an integrated framework of disrupted overall ocular surface homeostasis. In this view, the tear film is just one node in a network, and the chronic, refractory character of the disease emerges from interactions across the whole ocular surface rather than from a single deficit in tear production or stability.

According to the review, the pathological cascade begins with the corneal epithelium. When this thin protective layer is injured, its barrier function breaks down, and cells release damage-associated molecular patterns, molecular alarm signals that alert the innate immune system. Responding immune cells secrete abundant proinflammatory mediators, which in turn further impair epithelial architecture and damage goblet cells, the specialized cells that produce the mucus component of the tear film. The result is a feedback loop in which barrier failure fuels inflammation, and inflammation deepens barrier failure, setting the stage for disease chronicity.

The third player in the circuit, and arguably its central regulator, is the corneal nerve. The review describes how corneal nerves undergo both morphological and functional remodeling under chronic inflammatory and hyperosmotic stimuli. Patients and experimental models show reduced nerve fiber density alongside hyperalgesia, a state in which sensations become amplified and painful. At the same time, stressed nerves continuously secrete neuropeptides, signaling molecules that induce neurogenic inflammation, a form of immune activation driven directly by neural output. Neural dysfunction also suppresses tear secretion and hinders epithelial repair, so the very system meant to sense and protect the ocular surface becomes a persistent amplifier of immune dysregulation and tissue injury.

It is this three-way interdependence that the authors elevate into a formal conceptual model, which they call the epithelial–immune–neural unit. In their framework, a disrupted epithelial barrier releases inflammatory cytokines that trigger excessive immune activation and corneal neural damage. Injured nerves, in turn, secrete neuropeptides that further amplify immune responses. Sustained aberrant immune and neural signaling then jointly inhibit epithelial repair and regeneration. Because each compartment regulates the others bidirectionally, the system settles into a vicious cycle in which every round of injury primes the next. Analyses confined to any single compartment, the authors contend, cannot fully explain the diverse symptoms and chronic progression that define dry eye disease in the clinic.

The model has immediate explanatory power for a puzzle that has long frustrated clinicians: why symptoms so often persist even when tear quantity or quality appears to improve. If chronic pain and fluctuating vision are driven by neural remodeling and neurogenic inflammation rather than by the tear film alone, then therapies aimed solely at wetting the surface or broadly suppressing inflammation will leave key arms of the circuit untouched. The review systematically collates these interconnected mechanisms precisely because, in the authors’ assessment, no prior review had done so, leaving the field without a unified account of why the disease becomes refractory.

On the therapeutic side, the authors take a candid look at existing anti-inflammatory strategies and their inherent limitations. Their analysis clarifies the fundamental reason why single symptomatic interventions fail to block the vicious cycle of the tripartite system: a drug that targets only one arm of the network leaves the other two arms free to regenerate the pathology. Broad-spectrum anti-inflammatory approaches, while valuable, do not address the specific molecular conversations occurring between epithelium, immune cells, and nerves, and therefore cannot dismantle the circuit as a whole.

The prescription that follows is a change of paradigm. Yu, Wang, and Li propose that future clinical diagnosis and treatment should shift from the conventional broad-spectrum anti-inflammatory approach to precise regulation targeting the multidimensional pathological interactive network. In practice, that means diagnosing which components of the epithelial–immune–neural unit are driving disease in a given patient and intervening at the specific molecular nodes—cytokine signaling, innate immune activation, neuropeptide release, or neural repair pathways—that sustain the loop. Such targeted intervention strategies, the authors argue, are the logical next step for translational research built on the mechanistic system they describe.

The review also carries implications for how dry eye disease should be studied. By constructing an integrated unit model rather than cataloguing mechanisms compartment by compartment, the authors provide a theoretical scaffold for experiments that manipulate one arm of the circuit and measure consequences in the others. The work was supported by the National Natural Science Foundation of China and the Taishan Scholars Program, and it arrives at a moment when dry eye disease affects a large and growing share of the population worldwide, making mechanistically grounded, precision-oriented therapies an increasingly urgent clinical need.

For patients, the message of the review is quietly radical: dry eye disease is not merely dryness, and it should not be managed as such. It is a chronic inflammatory disorder of an integrated neuroimmune-epithelial system, in which damaged barriers, overactive immunity, and remodeling nerves feed one another in a loop that widens with time. Breaking that loop, the authors conclude, will require therapies designed for the network as a whole—precise, multidimensional regulation in place of one-size-fits-all symptom relief. If the field follows the roadmap laid out in this synthesis, the next generation of dry eye treatments may look far less like better eye drops and far more like targeted modulators of the biological circuit that keeps the disease alive.

Subject of Research: Inflammatory mechanisms and epithelial–immune–neural interactions in dry eye disease

Article Title: Inflammation as a central mechanism: interactions among epithelial, immune, and neural units in dry eye disease and their therapeutic implications

Article References: Yu, H., Wang, X., & Li, S. (2026). Inflammation as a central mechanism: interactions among epithelial, immune, and neural units in dry eye disease and their therapeutic implications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08891-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08891-8

Keywords: dry eye disease, inflammation, ocular surface, corneal nerves, epithelial barrier, innate immunity, neuropeptides, neurogenic inflammation, epithelial-immune-neural unit, targeted therapy, tear film, chronic disease

The research team, based at Ludwig-Maximilians-University Munich, took their laboratory into the field, following healthy volunteers on a five-day expedition through the Italian Alps in August 2022. Rather than simulating altitude in a hypoxic chamber, the investigators measured participants under genuine expedition conditions, ascending from the valley town of Varallo at 450 meters to the Capanna Regina Margherita at 4554 meters, one of the highest permanently staffed buildings in Europe. At each stage of the climb, participants completed structured headache questionnaires, rated their pain on a numerical scale from zero to ten, filled in the 2018 Lake Louise Acute Mountain Sickness Score, and provided samples of tear fluid for neuropeptide analysis. Certified mountain guides from the International Federation of Mountain Guides Association accompanied every group, and the protocol was approved by the university ethics committee.

The choice of tear fluid as the sampling medium is one of the study’s most intriguing technical features. Collecting blood at 4554 meters is cumbersome, and obtaining cerebrospinal fluid is out of the question in a field setting. Tear fluid, by contrast, can be aspirated from the lateral corner of each eye with a thin plastic capillary in under a minute, provided the investigator avoids irritating the ocular surface and triggering reflex tearing, which would dilute the sample. The researchers collected fluid from both eyes, pooled it after confirming no significant left-right differences at baseline, stabilized it in protein extraction reagent, kept it on dry ice, and later quantified CGRP concentrations with a commercial enzyme-linked immunosorbent assay read in duplicate on a spectrometer. The approach offers a noninvasive window into a neuropeptide that is otherwise difficult to track outside a hospital laboratory.

CGRP itself is a potent vasodilatory neuropeptide released from the endings of the trigeminovascular system, the network of sensory nerves that innervates the blood vessels of the brain’s protective membranes. Decades of work have established it as a central player in migraine: levels rise during spontaneous attacks, injecting CGRP can provoke migraine-like headaches in susceptible patients, and drugs that block the molecule or its receptor have transformed migraine prevention in recent years. Because high-altitude headache shares clinical features with migraine, including aggravation by physical activity, and because a history of migraine is a known risk factor for altitude headache, the Munich team hypothesized that hypobaric hypoxia might activate the same trigeminovascular pathway and drive CGRP release at altitude.

The expedition data gave that hypothesis substantial support. Of the 24 originally recruited participants, 13 completed the full protocol with usable tear samples, a reduction the authors attribute to early terminations and insufficient fluid volumes. Among these 13, headache burden climbed steadily with altitude. No one reported headache at baseline in the valley, but 46 percent did so after reaching 3498 meters on day two, 62 percent at 3647 meters on day three, and a striking 85 percent at 4554 meters on day four, when the mean pain score reached 3.2 on the ten-point scale. Eight participants, or 62 percent, fulfilled the formal ICHD-3 criteria for high-altitude headache at the highest hut, a figure consistent with the 36 to 73 percent incidence reported in earlier studies at comparable elevations.

The CGRP measurements revealed a pattern that was invisible in the group average. Across all participants, tear fluid CGRP levels at 4554 meters were not significantly different from baseline values, a result that on its own might have suggested the neuropeptide was irrelevant. But when the researchers split the cohort by symptom severity, a clear signal emerged. The six participants who developed moderate-to-severe headaches, with mean pain scores of 5.0, showed a substantial rise in tear fluid CGRP, averaging an increase of 1.86 nanograms per milliliter from baseline, while the seven participants with only mild headaches actually showed a slight decrease of 0.19 nanograms per milliliter. The difference between the groups was statistically significant, and baseline CGRP levels had been virtually identical, indicating that the elevation was triggered by the altitude exposure itself rather than reflecting a pre-existing trait.

The same dissociation appeared when participants were classified by diagnosis. Those meeting ICHD-3 criteria for high-altitude headache showed a mean CGRP increase of 1.49 nanograms per milliliter, compared with a decrease of 0.42 in those without the diagnosis. Even more striking, six participants, nearly half the cohort, developed a headache that met criteria for migraine without aura, complete with moderate-to-severe pulsating pain, nausea or vomiting in half of cases, and photophobia in some. These migraine-like sufferers reported higher pain intensity and a significantly larger CGRP rise of 1.75 nanograms per milliliter than their symptom-free counterparts. Notably, oxygen saturation, which hovered around 78 percent at the highest altitude for everyone, did not differ between headache and non-headache groups, suggesting that the degree of hypoxia alone did not determine who suffered.

The cerebral circulation told a quieter story. Using transcranial color-coded duplex sonography at baseline and at 4554 meters, the team measured blood flow velocity in the middle cerebral arteries on both sides, calculating mean flow velocities and the Lindegaard index to screen for vasospasm. Neither the presence of high-altitude headache nor of migraine-like symptoms was associated with differences in flow velocity or in the change from baseline, and there was no evidence of vasospasm in any group. This absence of a vascular signature is itself informative: it shifts attention away from simple blood-vessel constriction or dilation as the cause of altitude pain and toward neurogenic inflammation, the process by which activated trigeminal nerves release CGRP and other mediators directly around meningeal vessels.

Disentangling the two candidate triggers of that activation, hypoxia and reduced barometric pressure, remains difficult in a field design, and the authors are careful on this point. Animal experiments have shown that lowering atmospheric pressure by as little as 40 hectopascals increases firing in neurons of the spinal trigeminal nucleus, particularly those with corneal afferents, and human volunteers exposed to modest pressure drops in a climate chamber have reported head compression and mild-to-moderate headache. Meanwhile, chamber studies of pure normobaric hypoxia have induced headache in roughly 80 percent of healthy volunteers and elevated plasma CGRP in migraine patients. Because tear fluid CGRP did not rise uniformly across the expedition and did not track oxygen saturation, the new data hint that hypoxia by itself may be insufficient, and that the interplay of low pressure and low oxygen, possibly amplified in susceptible individuals, is what ignites the trigeminovascular system.

The study’s limitations are real and acknowledged by its authors. Thirteen completers is a small sample, nearly half the original cohort was excluded, tear fluid CGRP has not been formally validated against plasma or cerebrospinal fluid concentrations, and an observational design cannot establish whether the neuropeptide rise precedes the pain or merely accompanies it. Even so, the implications are tantalizing. If CGRP release genuinely drives altitude headache, then the CGRP-targeted monoclonal antibodies and small-molecule antagonists that have revolutionized migraine care might, in principle, be repurposed as prophylaxis for mountaineers, an idea the authors say deserves interventional study. And if tear fluid proves to be a reliable surrogate medium, field researchers could gain a practical, needle-free biomarker for headache severity in some of the most remote environments on Earth, from Himalayan base camps to aerospace settings, where the biology of low pressure and low oxygen has long outpaced our ability to measure it.

Subject of Research: The role of the neuropeptide CGRP in high-altitude headache and migraine-like headache during hypobaric hypoxia

Article Title: The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study

Article References: Schniepp, R., Karrasch, L., Breitenstein, H., Straube, A., & Kamm, K. (2026). The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study. Annals of Clinical and Translational Neurology, 13(10), 2046-2056. https://doi.org/10.1002/acn3.70374

Image Credits: AI Generated

DOI: 10.1002/acn3.70374

Keywords: high-altitude headache, CGRP, migraine, hypobaric hypoxia, trigeminovascular system, tear fluid biomarker, acute mountain sickness, transcranial duplex sonography, neuropeptides, Alps expedition, headache disorders, neurology

The parabrachial nucleus, a compact structure tucked into the dorsolateral pons, has long been recognized as a major relay station for alarm signals traveling from the body and spinal cord up to forebrain circuits. CGRP-expressing neurons in this region project densely to the central amygdala, the bed nucleus of the stria terminalis and other threat-processing hubs, and earlier work established that artificially activating these neurons produces powerful aversive states and widespread fear-like responses. What remained less clear was whether CGRP signaling in the parabrachial nucleus influences not just the intensity of fear, but the specific behavioral form that fear takes, an issue the new study set out to address directly.

To do so, the researchers employed a platform-based active avoidance paradigm, an experimental setup in which a rodent can terminate or avoid an aversive stimulus by moving onto a raised platform. Unlike classical Pavlovian fear-conditioning assays, which measure freezing as the primary output, active avoidance tasks capture the animal’s capacity to translate threat detection into goal-directed escape behavior. This distinction is crucial, because freezing and active avoidance are not simply different intensities of the same response; they represent distinct defensive strategies governed by partially separable neural circuits, and animals typically select between them based on factors such as the distance to the threat, the availability of escape routes and previous experience with the environment.

The central manipulation involved pharmacological or chemogenetic inhibition of CGRP signaling within the parabrachial nucleus. When CGRP activity was suppressed, the researchers observed a striking reorganization of defensive behavior: animals spent less time in the passive, immobile freezing posture that normally dominates their response to learned threat cues, and instead escalated their engagement with the active avoidance strategy, rapidly locating and mounting the escape platform. In other words, dampening CGRP did not blunt fear altogether, as one might naively predict if the peptide were simply a universal fear amplifier. Rather, it redirected the defensive response, channeling the animal’s motivational energy from one stereotyped strategy into another.

This dissociation carries substantial theoretical weight. Classical models of fear conditioning have often treated freezing as the canonical index of conditioned fear, so much so that a pharmacological intervention reducing freezing would conventionally be interpreted as anxiolytic or fear-reducing. The new results challenge that inference. Animals with inhibited parabrachial CGRP signaling were not less afraid; they were differently afraid, mobilizing an active coping strategy in place of an immobile one. The study therefore reinforces an increasingly influential view in behavioral neuroscience: that fear must be measured across a repertoire of adaptive responses, and that single-measure assays can systematically mischaracterize the effects of neural or pharmacological manipulations.

From a mechanistic standpoint, the findings suggest that CGRP neurons in the parabrachial nucleus act as a biasing signal within a distributed defensive decision network. These neurons are well positioned for such a role. They integrate interoceptive alarm signals, including those carried by the spinal trigeminal and lamina I spinothalamic pathways, and broadcast the resulting arousal state to forebrain structures that execute specific defensive programs. Projections to the central amygdala have been implicated in promoting passive defensive reactions, whereas circuits running through the ventrolateral periaqueductal gray and basal ganglia loops are more closely associated with active escape and avoidance. By altering the gain of CGRP signaling at the source, the manipulation appears to rebalance competition between these downstream effectors, tilting the system toward the active option.

The platform-based paradigm proved especially informative because it allowed within-subject quantification of both response types. Rather than relying on separate cohorts of freezing-conditioned and shuttle-box-trained animals, the researchers could observe individual animals distributing their behavior between immobility and platform escape across trials. This design revealed that the shift from freezing to avoidance was not a threshold artifact or a byproduct of altered shock sensitivity; instead, it reflected a genuine reweighting of strategy selection, consistent with a decision-level function for parabrachial CGRP rather than a purely sensory or motor role.

The translational implications are significant, particularly for post-traumatic stress disorder and other trauma- and anxiety-related conditions in which patients exhibit maladaptive defensive postures. Human PTSD is often characterized not only by exaggerated fear responses but by inflexibility in choosing among coping strategies, including a failure to engage active avoidance or escape behaviors that might reduce harm. If CGRP signaling in the parabrachial-amygdala pathway similarly constrains active coping in humans, drugs that modulate CGRP receptors, a class already developed and clinically validated for migraine prophylaxis through gepant compounds, could conceivably be repurposed or re-evaluated for their effects on defensive strategy selection. The new study does not establish such clinical effects, but it provides a rigorous animal-model foundation for asking the question.

More broadly, the work exemplifies a shift in how learning and memory research frames threat-related behavior. Instead of treating fear as a unitary internal state read out through a single behavioral channel, contemporary neuroscience increasingly emphasizes a menu of genetically and anatomically specified defensive circuits whose relative activation determines the observable strategy. CGRP neurons in the parabrachial nucleus now appear to be one of the clearest molecularly identifiable control points for that selection process. By demonstrating that inhibition of this specific neuropeptide population reconfigures, rather than diminishes, defensive behavior, the study offers both a conceptual lesson, that fear research must account for strategy switching, and a practical one, that assays capturing active coping are indispensable for interpreting interventions aimed at threat-related circuitry. As attention turns to how upstream inputs and downstream targets partition the freezing-versus-avoidance decision, the parabrachial CGRP system is likely to remain a focal point for understanding how brains choose how to be afraid.

Subject of Research: Role of CGRP neurons in the parabrachial nucleus in selecting between freezing and active avoidance defensive strategies

Article Title: CGRP inhibition in the PBN shifts defensive strategy from freezing to active avoidance in a platform-based active avoidance paradigm

Article References: Lee, H. H., Han, E., & Jo, Y. S. (2026). CGRP inhibition in the PBN shifts defensive strategy from freezing to active avoidance in a platform-based active avoidance paradigm. npj Science of Learning. https://doi.org/10.1038/s41539-026-00453-3

Image Credits: AI Generated

DOI: 10.1038/s41539-026-00453-3

Keywords: CGRP, parabrachial nucleus, active avoidance, freezing, fear conditioning, defensive behavior, threat processing, amygdala, neuropeptides, behavioral neuroscience, PTSD, platform-based avoidance paradigm